Articles related to FDA

The recent approval of epcoritamab for R/R DLBCL introduces a new pathway in treatment, offering substantial response rates and the potential for broader implementation beyond academic centers. Explore the detailed insights into the function, efficacy, and prospective implications of this novel therapy.

Suflave™, an osmotic laxative approved by the FDA for colon cleansing in adults, represents a significant development in colonoscopy preparation. Patients interested in a low-volume option with improved taste attributes will find Suflave to be a promising alternative.

The FDA’s approval of Beyfortus offers a promising tool for RSV disease prevention in neonates and young children. This novel intervention, underscored by robust clinical trial data, marks a crucial stride towards protecting infant health in the US.

Brenzavvy, the latest addition to the diabetes treatment landscape, promises a cost-effective approach to managing type 2 diabetes. Discover how this newly approved drug could redefine the treatment paradigm for patients.

FDA’s approval of Opill, the first over-the-counter daily oral contraceptive, marks a major shift in contraceptive accessibility, opening new pathways in the prevention of unintended pregnancies.

As the FDA approves the first over-the-counter oral contraceptive, dental professionals must be cognizant of potential impacts on oral health and patient management.